ArticleJournal of nanobiotechnology2022
Magnetic, biocompatible FeCO
Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Ferrocene-Functionalized Black Phosphorus Nanoplatform Enables Targeted and Prolonged MRI Visualization of Atherosclerotic Plaques.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Applications of Matrix Metalloproteinase-9-Related Nanomedicines in Tumors and Vascular Diseases.Pharmaceutics · 2025Review
- Iodinated gadolinium-gold nanomaterial as a multimodal contrast agent for cartilage tissue imaging.APL bioengineering · 2024Article
- Magneto-optical nanosystems for tumor multimodal imaging and therapyMaterials today. Bio · 2024Review
- EP300 regulates the SLC16A1-AS1-AS1/TCF3 axis to promote lung cancer malignancies through the Wnt signaling pathway.Heliyon · 2024Article
- Article
- Recent advances in melittin-based nanoparticles for antitumor treatment: from mechanisms to targeted delivery strategies.Journal of nanobiotechnology · 2023Review
- Article
- Modified gefitinib conjugated FeFrontiers in bioengineering and biotechnology · 2023Article
- Advances in nanotechnology-based targeted-contrast agents for computed tomography and magnetic resonance.Science progressReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLate diagnosis of lung cancer is one of the leading causes of higher mortality in lung cancer patients worldwide. Significant research attention has focused on the use of magnetic resonance imaging (MRI) based nano contrast agents to efficiently locate cancer tumors for surgical removal or disease diagnostics. Although contrast agents offer significant advantages, further clinical applications require improvements in biocompatibility, biosafety and efficacy.
resultsTo address these challenges, we fabricated ultra-fine Iron Carbonate Nanoparticles (FeCO
conclusionThe excellent biocompatibility and T2 weighted contrast abilities of FeCO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.